Chimerix to Showcase Innovation at Precision Medicine Symposium
Chimerix, a prominent biopharmaceutical company dedicated to creating life-changing medicines, has announced an exciting opportunity for industry engagement. Mike Andriole, the Chief Executive Officer, along with Tom Riga, the Chief Operating and Commercial Officer, will participate in a fireside chat at the upcoming JonesTrading Virtual Precision Medicine Symposium. This event is scheduled for Monday, February 3, 2025, at 11:00 a.m. ET.
Insights into the Future of Medicine
The futures of healthcare and biopharmaceuticals are increasingly intertwined. During the symposium, Chimerix's executives will share insights into their pioneering work aimed at improving patient outcomes in the face of life-threatening conditions. This chat will feature critical discussions surrounding their innovative research and development strategies, particularly how they align with the modern landscape of precision medicine.
Exploring Advanced Development Programs
Chimerix's standout development program, dordaviprone, is specifically targeted at H3 K27M-mutant glioma. Glioma is a challenging and aggressive form of brain cancer that impacts many lives. The development team is making strides, conducting Phase 1 dose escalation studies of another promising therapy, ONC206. This study focuses on safety and pharmacokinetic (PK) data, crucial for understanding how the body processes this innovative treatment.
Staying Connected with Investors
Participants interested in the symposium can tune in via an audio webcast that will be made available on the Investor Relations section of Chimerix's official website. This archived session will remain accessible for about 90 days, allowing for broader accessibility to investors and stakeholders who want to stay informed about Chimerix's latest advancements and strategic directions.
About the Company
At its core, Chimerix is guided by a robust mission: to develop medicines that significantly extend and improve the lives of patients battling severe diseases. The commitment to this mission drives their research initiatives, leading to advancements that could offer new hope to patients worldwide.
Contact Information for Interested Parties
For those looking to reach out for more information regarding this event or Chimerix's ongoing projects, the company is open for communication. Will O’Connor from Stern Investor Relations is the designated investor contact, and he can be reached through email. Additionally, media inquiries can be directed to Dana Davis at Steelwire, ensuring that all aspects of communication are well-handled.
Frequently Asked Questions
What is the focus of Chimerix's participation in the symposium?
Chimerix will highlight its innovative approaches in the development of therapies for deadly diseases during the chat.
Who are the key speakers at the fireside chat?
Mike Andriole, the CEO, and Tom Riga, the Chief Operating and Commercial Officer, will lead the discussion.
What topics will be discussed regarding drug development?
The discussion will primarily focus on dordaviprone and ONC206, including the latest findings from their research efforts.
How can one access the symposium?
Attendees can watch the session via an audio webcast on Chimerix’s Investor Relations website.
Is there a way to contact Chimerix for further inquiries?
Yes, Will O’Connor and Dana Davis can be contacted for investor and media inquiries respectively.
